Full-Time

Scientist – Radiochemistry

Confirmed live in the last 24 hours

Deadline 6/30/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

No salary listed

Mid, Senior

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Category
Lab & Research
Medical Research
Requirements
  • Candidates must have a Ph.D. in organic chemistry with 0-5 years of additional related research experience.
  • Candidates must have basic experience in PET radiochemistry designing and executing radiochemical syntheses, using any of the common PET isotopes including 11C, 18F, 68Ga, 64Cu and/or 89Zr.
  • Candidates must have expertise in the synthesis, purification and characterization of PET radiolabeled compounds using modern remote controlled synthesis units and chromatography, NMR, and LC/MS.
  • Excellent problem-solving skills and a thorough understanding of synthetic methods and reaction mechanisms are required.
  • Good oral/written communication skills and a commitment to safety are necessary.
Responsibilities
  • This individual will be responsible for the design and synthesis of PET radioligands as non-invasive biomarkers needed within drug discovery and development.
  • The individual will apply modern techniques in organic chemistry, PET radiochemistry and utilize current medicinal chemistry practices to go wherever the science leads to solve relevant problems.
  • The individual will be expected to work well as part of a multidisciplinary team.
  • The position will involve working independently and alongside senior team members to gain experience and knowledge in the areas of PET synthesis and medicinal chemistry.
  • Daily work will include manipulating high-energy PET isotopes using state-of-the-art containment and remote synthesis facilities including a cyclotron.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high safety and quality standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's $40B US investment signals strong commitment to growth despite cost-cutting.
  • AI partnership with Optellum enhances early lung cancer diagnosis and precision care.
  • Expansion in Gulf region under new leadership boosts market presence and opportunities.

What critics are saying

  • Layoffs and facility closures may disrupt production and market demand fulfillment.
  • New leadership appointments could shift company policy, impacting ongoing projects.
  • Acquisition of 2seventy bio may pose integration challenges affecting operational efficiency.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases, setting it apart in biopharma.
  • The company invests heavily in R&D to develop innovative and generic medicines.
  • BMS emphasizes sustainability and ESG goals, enhancing its corporate responsibility image.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

BioSpace
May 6th, 2025
BMS Pledges $40B Investment in US Despite Cost-Cutting Plans

This year alone BMS has laid off more than 800 employees, the bulk of which were just revealed this month, putting 516 jobs on the chopping block.

ROI-NJ
May 6th, 2025
Bristol Myers Squibb Names Gallman Executive Vp, General Counsel And Chief Policy Officer

Bristol Myers Squibb, the fourth-largest company in New Jersey by market cap, announced Tuesday the appointment of Cari Gallman as executive vice president, general counsel and chief policy officer, effective immediately. She succeeds Sandra (Sandy) Leung, who is retiring after a 33-year career at the company.Gallman has extensive experience in pharmaceutical law and compliance. She will lead the law department, which includes intellectual property, commercial and regulatory law, litigation, securities and corporate governance, transactions, corporate security and compliance and ethics, as well as global and U.S. policy and government affairs. Gallman has held leadership positions at Bristol Myers Squibb for 10 years, most recently serving as executive vice president, corporate affairs.“I am committed to continuing to build on the company’s culture of integrity and shape a dynamic policy environment that protects innovation and patients,” said Gallman in a statement.Gallman began her legal career in private practice representing pharmaceutical and medical device manufacturers in civil, regulatory, and government enforcement matters.She earned a bachelor’s degree in political theory from Princeton University, magna cum laude, and holds a juris doctor degree from Harvard Law School

Endpoints News
May 5th, 2025
Bristol Myers to lay off over 500 workers in New Jersey

Bristol Myers to lay off over 500 workers in New Jersey.

NJBIZ
May 5th, 2025
Bristol Myers Squibb plans 500+ layoffs in NJ

BMS recently announced plans to close a manufacturing facility in Illinois that handles viral vector production.

All Blog Things
May 3rd, 2025
BMS to lay off 516 employees at its Lawrence Township facility

BMS to lay off 516 employees at its Lawrence Township facility.